$1.5 Trillion Mid-Size Pharmaceutical Market: Market Assessment, Growth Forecasts and Strategic Consolidations for Key Players to 2021 – ResearchAndMarkets.com

Mid-Size Pharmaceutical Market: Market Assessment, Growth Forecasts and
Strategic Consolidations for Key Players”
report has been added
to ResearchAndMarkets.com’s offering.

The worldwide pharmaceutical market is projected to grow from
approximately $1.1 trillion in 2016 to $1.5 trillion in 2021,
representing a compound annual growth rate of 6.4%.

“The Mid-Size Pharmaceutical Market: Market Assessment, Growth Forecasts
and Strategic Consolidations for Key Players” focuses on comparative
analysis of mid-size pharma companies and the strategies followed in
order to sustain and grow in the market, from data covering over 80
mid-size companies both those focused exclusively on pharma, and those
also involved in other divisions of healthcare, such as medical devices,
in addition to pharma products.

The ten major developed markets are expected to cover 67% of global
spending by 2021, which is 1% less than their share in 2016. Growth will
be driven by global demographic and economic trends, including a rapidly
aging global population and an associated rise in chronic diseases;
increased urbanization; higher disposable income; greater government
expenditure on healthcare; and growing demand for more effective

The pharmaceutical sector can be divided into various categories based
on revenue, comprising large, mid-size and small pharma companies. The
mid-size sector, which is the focus of this report, consists of 82
companies with revenue ranging from $1 billion to $10 billion, while
small and large companies fall below and above this threshold,

Most mid-size pharma companies are focusing heavily on developing a
portfolio of generic products covering a variety of therapy areas and
geographies. Additionally, the top mid-size companies are involved in
the end-to-end development of innovative products, although in these
cases their focus is limited to specific therapy areas.

A few mid-size companies diverge from the typical trends and are
particularly focused on rare diseases, such as the Alexion
Pharmaceuticals. In these ways mid-size companies can be seen to be
different to large pharma companies, which almost all focus on
end-to-end product development covering a variety of therapy areas and
geographies. Large pharma companies have sufficient investment
capability and human resources to support a wider variety of R&D
activities than mid-size pharma.

Key Topics Covered:

1. Introduction

  • What is the Mid-Sized Pharma Segment and What is its Role in the
  • Why is Mid-size Pharma a Key Element of the Industry?

2. Mid-size Pharma Players with Revenue Forecasts

  • Comparative Analysis and Ranking – Based on Revenue
  • R&D Expenditure
  • Number of Pipeline Products
  • Number of Marketed Products
  • Number of Employees
  • Location of Headquarter
  • Year-on-Year Revenue
  • Year-on-Year R&D Expenditure

3. Key Points

  • Mid-size Pharma Companies – Growth Strategies related to Deals and
  • Mergers and Acquisitions
  • Licensing Agreements and Partnerships
  • R&D Collaboration
  • Geographical Expansion
  • In-House Research and Development
  • Shift towards High-Value Generics from Low-Value Generics
  • Brand Building
  • Specialized Therapy Areas and Rare Diseases

4. Top Mid-size Pharma Companies

  • Daiichi Sankyo
  • Valeant Pharmaceuticals
  • Eisai
  • Regeneron Pharmaceuticals
  • UCB
  • Les Laboratories Servier
  • Sun Pharmaceutical
  • Endo International
  • Mallinckrodt
  • Kyowa Hakko Kirin
  • Alexion Pharmaceuticals
  • Taisho Pharmaceutical

5. Overview

  • Top Marketed Products
  • Pipeline Overview
  • Late stage Products with Sales Forecast
  • Revenue Forecast
  • Deals by Value and Volume
  • Key Deals

6. Top Small Pharma Companies Likely to Enter the Mid-size Segment

  • Horizon Pharma
  • Intas Pharmaceuticals
  • Hypermarcas

7. Challenges Faced by Mid-size Pharma

8. Conclusion

9. List of Mid-size Pharma Companies

10. Bibliography

For more information about this report visit https://www.researchandmarkets.com/research/r7xdh3/1_5_trillion?w=4


Laura Wood, Senior Manager
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
For GMT Office Hours Call +353-1-416-8900
Topics: Pharmaceuticals